The hypoxanthine-guanine phosphoribosyltransferase (HGPRT) enzyme of Trypanosoma brucei and related parasites provides a rational target for the treatment of African sleeping sickness and several other parasitic diseases. To characterize the T. brucei HGPRT enzyme in detail, the T. brucei hgprt was isolated within a 4.2 kb Sal\-Kpn\ genomic insert and sequenced. Nucleotide sequence analysis revealed an open reading frame of 630 bp that encoded a protein of 210 amino acids with a M r = 23.4 kd. After gap alignment, the T. brucei HGPRT exhibited 21 -23 % amino acid sequence identity, mostly in three clustered regions, with the HGPRTs from human, S. mansoni, and P. falciparum, indicating that the trypanosome enzyme was the most divergent of the group. Surprisingly, the T. brucei HGPRT was more homologous to the hypoxanthine phosphoribosyltransferase (HPRT) from the prokaryote V. harveyi than to the eukaryotic HGPRTs. Northern blot analysis revealed two trypanosome transcripts of 1.4 and 1.9 kb, each expressed to equivalent degrees in insect vector and mammalian forms of the parasite. The T. brucei hgprt was inserted into an expression plasmid and transformed into S<£606 E. coli that are deficient in both HPRT and xanthine-guanine phosphoribosyltransferase activities. Soluble, enzymatically active recombinant T. brucei HGPRT was expressed to high levels and purified to homogeneity by GTP-agarose affinity chromatography. The purified recombinant enzyme recognized hypoxanthine, guanine, and allopurinol, but not xanthine or adenine, as substrates and was inhibited by a variety of nucleotide effectors. The availability of a molecular clone encoding the T. brucei hgprt and large quantities of homogeneous recombinant HGPRT enzyme provides an experimentally manipulate molecular and biochemical system for the rational design of novel therapeutic agents for the treatment of African sleeping sickness and other diseases of parasitic origin.
INTRODUCTION
Trypanosoma brucei is a protozoan parasite that is the etiologic agent of African sleeping sickness, a devastating and often fatal disease in humans, and nagana, a deadly disease of domestic animals. Transmitted to humans by the bite of an infected tsetse fly, T. brucei inhabit and replicate exclusively within extracellular milieus of the host. The conventional therapeutic agents for the treatment of African sleeping sickness are far from ideal since these drugs are ineffective after central nervous system involvement and have numerous undesirable side effects due to their lack of selectivity for the metabolic machinery of the parasite. Furthermore, treatment of African sleeping sickness is often complicated by chemotherapeutic failure, a predicament that is often attributed to drug resistance (1) (2) (3) .
Selective and rational therapies for parasitic diseases have been generally difficult to devise since many of the major metabolic pathways in these lower eukaryotes are similar, if not identical, to those in their vertebrate host. One metabolic pathway that is conspicuously different between parasites and humans is that for the production of purine nucleotides. Whereas mammalian cells synthesize purine nucleotides de novo, all genera of parasitic protozoa that have been examined are auxotrophic for purines (4) (5) (6) (7) (8) (9) (10) (11) (12) . In order to satisfy their purine requirements, each genus of parasite has evolved a unique complement of purine salvage enzymes for which no identical mammalian counterpart exists. Biochemical and metabolic studies have substantiated the existence of a plethora of purine salvage enzymes in T. brucei, including phosphoribosyltransferases (PRTs), nucleoside kinases, and nucleoside cleavage activities (10, 13, 14) . The unique features of the purine salvage system of T. brucei and the related parasites Trypanosoma cruzi and Leishmania cause these pathogenic hemoflagellates to be selectively susceptible to the cytotoxic effects of several pyrazolopyrimidine analogs of hypoxanthine and inosine (15, 16) . For instance, T. b. brucei, T. b. gambiense, and T. b. rhodiensese bloodstream forms are all sensitive to allopurinol (HPP) (17) , a pyrazolopyrimidine isomer of hypoxanthine that is nontoxic to humans and used extensively in the treatment of hyperuricemia and gout (18) .
Metabolic activation of HPP in T. brucei, as well as in Leishmania and T. cruzi, is initiated by the enzyme hypoxanthine- : To whom correspondence should be addressed guanine phosphoribosyltransferase (HGPRT: MP:pyrophosphate phosphoribosyltransferase, EC 2.4.2.8). The unique substrate specificity of the HGPRT enzyme of these parasites suggests that the enzyme may serve as a rational target for antiparasitic drugs. To characterize this therapeutically germane enzyme further and to develop molecular reagents for future studies directed toward structure-based drug design, we have cloned and sequenced the hgprt from T. brucei. Furthermore, the parasite hgprt has been inserted into an expression vector, expressed to very high levels in E. coli, and large quantities of recombinant HGPRT have been purified to homogeneity. 
MATERIALS AND METHODS

Isolation of a T. brucei hgprt fragment by the polymerase chain reaction
To generate a homologous DNA probe for the isolation of the T. brucei hgprt, a fragment of the gene was amplified from genomic DNA in the polymerase chain reaction (PCR) using degenerate oligonucleotide primers created from completely conserved amino acid sequences on the mammalian (22, 23) , Schistosoma mansoni (24) , and Plasmodium falciparum ( GJAA-3', was synthesized with an £coRI site preceded by a 3 nucleotide leader 5' to a mixed oligonucleotide generated from residues 187-191, FVVGY, of the human HGPRT. Amplification of the specific hgprt fragment was accomplished on a Coy Instruments (Ann Arbor, MI) thermocycler using the amplification assay mixture described by Hanson et al. (26) . The sample was subjected to 30 cycles of denaturation at 94 °C for 0.5 min, annealing at 40°C for 0.5 min, and extension at 72°C 1.0 min. The PCR products were ligated into pBluescript KS + vector obtained from Stratagene (San Diego, CA), and transformed into XL-1 Blue Escherichia coli. Large scale plasmid preparations were prepared according to the large scale alkaline lysis protocol (27) . The 174 bp hgprt fragment was sequenced according to the dideoxy chain termination method (28) 
Isolation of the hgprt from T. brucei libraries
The T. brucei hgprt was isolated from the T. brucei genomic library in two steps. First, the amplified hgprt PCR product was employed as a probe to screen the T. brucei cDNA library, and second, an hgprt cDNA that lacked the 5' protein coding portion of the hgprt was used to screen the genomic library. The prehybridization, hybridization, and washing conditions employed to isolate the hgprt cDNAs and genomic locus were identical to those described previously by this laboratory for the isolation of the L. donovani ornithine decarboxylase (ODC) gene (26) . Positive bacteriophage from each library were carried through a tertiary plaque purification, and their DNA was isolated by CsCl density gradient centrifugation (29) .
Subcloning and sequencing of T, brucei hgprt
The lengths of the hgprt inserts from the cDNA library were determined on 0.8% agarose gels, and the longest cDNA, a 1.4 kb fragment, was ligated into pBluescript KS + and transformed into XL-1 Blue E. coli. DNA from the genomic clones was probed with the 1.4 kb hgprt cDNA under the same high stringency conditions employed for screening the libraries and a 4.2 kb SaR-Kpnl genomic fragment was isolated as described for the cDNAs. Large scale plasmid preparations and nucleotide sequencing of DNA were performed as described above for the PCR fragment.
Computer assisted DNA and amino acid sequence analysis Analyses of nucleotide and predicted amino acid sequences were performed on an IBM compatible AT computer using the Sequence Analysis Program from International Biotechnologies, Inc. (New Haven, CT). Protein sequences were aligned using the CLUSTAL V multiple sequence alignment program, a modification of the CLUSTAL package described by Higgins and Sharp (30) . Amino acid similarity scores between nonidentical amino acid pairs were obtained from the log-odds amino acid similarity matrix of Dayhoff (31) .
Southern and Northern analyses
Southern blots of restriction enzyme-cleaved TREU667 genomic DNA were performed under standard conditions (29) . A Northern blot of RNA isolated from bloodstream and procyclic forms of IsTAR 1 T. brucei was hybridized to the hgprt under the same high stringency conditions described for probing the Southern blots. The Northern blot was contributed by Dr Parsons.
Mapping the 5' terminus of the mature hgprt mRNA The 5' terminus of the mature T. brucei hgprt transcript was defined by a modification of the PCR amplification protocol reported by Hanson et al. (26) . cDNA synthesis from total RNA was achieved with random hexamer primers using the reverse transciptase (RT) protocol described by Kawasaki (32) . The RT mixture was then adjusted to 10 mM Tris-HCl, pH 8.3, 50 mM KC1, and 1.5 mM MgCl 2 , and 10 pmol of each oligonucleotide primer and 5 units of Taq DNA polymerase were added. The sense primer, 5'-CTCGGGATCCCAACGCTATATAAGTA-TCAGTTTCTGTACTTTATTG-3', contained an 11 nucleotide leader containing a BamYK restriction site followed by 31 nucleotides matching positions 5-35 of the L. donovani miniexon (33) . The mini-exon is an RNA that is taj/u-spliced onto the 5' end of all mRNAs from Trypanosoma and Leishmania species (34, 35) . Of the 31 nucleotides of the sense primer, the T. brucei and L. donovani mini-exon genes differ in only 4 positions. The antisense primer, 5'-CTCGAATTCGCTGCCC-TTCAATACAGA-3', was constructed to nucleotides 151-168 of the protein coding portion of the T. brucei hgprt and contained a 9 nucleotide leader enclosing an £coRI recognition site. The PCR sample was incubated at 94, 50, and 72°C, respectively, for 35 cycles in the thermocycler. A 250 bp PCR product that hybridized to the T. brucei hgprt was subcloned and sequenced as described above.
Overexpression of T.brucei hgprt in E.coli
The T. brucei hgprt was ligated into the pBAce expression vector constructed by Craig et al. (36) . An Ndel restriction site was introduced at the initiation Met codon and a Sail cleavage site was inserted 3' to the termination signal by PCR mutagenesis in two separate amplification reactions, necessitated by the presence of an internal Ndel site within the T. brucei hgprt. The 5' end of the hgprt was amplified using 5'-TCTCATATGGAA-CCAGCTTGCAAATA-3' as the mutagenic primer and 5'-GT-AGGAATTCCACACGTGTGG-3' as the antisense primer containing an internal EcoRI cleavage site. The 3' end of the gene was amplified using 5'-TGTGGAATTCCTGCGGGCCT-C-3' containing the same internal EcoRI site as the sense primer and the mutagenic 5'-TCTGTCGACACAAGGCACAAGAGC-TACCTG-3' as the antisense primer. The two PCR fragments were digested with the appropriate restriction enzymes and ligated simultaneously into pBAce that had been cleaved with Ndel and Sail. The ligation mixture was transformed into the E. coli K-12 strain S#606 (Agpt-pro-lac, thi, hpt) that was initially described (37) and generously provided to this laboratory by Dr Per Nygaard of the University Institute of Biological Chemistry B (Copenhagen, Denmark) through Dr Sidney Craig of the University of California (San Francisco, CA). This strain contains a deletion in the gene encoding the bacterial xanthine-guanine phosphoribosyltransferase (XGPRT) activity and is also deficient in hypoxanthine phosphoribosyltransferase (HPRT) activity. DNA was prepared from the transformants, and the 630 bp NdelSatl fragment containing the entire T. brucei hgprt was sequenced in both directions. 500 ml cultures of S$6O6 cells transformed with the recombinant expression plasmid were incubated in a low phosphate medium modified from that previously described (36) by reducing the concentration of 'vitamin free' Casamino acids (Difco Laboratories, Detroit, MI) to 0.1 % and deleting the equimolar mixture of NaH 2 PO 4 and Na 2 HPO 4 . The adjustments were crucial for maximizing expression of recombinant protein, as the 'vitamin free' Casamino acids contained 100 /tmol/g of inorganic phosphate. The final concentration of phosphate in the modified induction medium was, therefore, -100 jiM.
Inorganic phosphate assay Inorganic phosphate levels in the hgprt expression medium were determined as described (38) .
HGPRT assay HGPRT activity was assayed as previously reported (39) . The rates of [ HGPRT purification Recombinant T. brucei HGPRT was purified by a modification of the method described by Allen et al. (39) for the purification of native HGPRT from L. donovani. 500 ml cultures of S06O6 E. coli were grown for 12 hr at 37°C to an ODgoo = 0.9-1.2. The cells were washed several times with phosphate buffered saline (137 mM NaCl, 2.7 mM KC1, 8.1 mM Na 2 HPO 4 , and 1.0 mM KH 2 PO 4 ) and lysed by French press in 20 mM Tris, pH 7.4, 5 mM MgCl 2 , and lmM dithiothreitol (TMD) buffer. After centrifugation at 40,000xg for 30 min at 4°C, the cell supernatant was chromatographed over a 10 ml GTP-agarose affinity column. The column was then washed with 10 column volumes of TMD and the protein eluted in TMD containing 1.0 mM PRPP.
Polyacrylamide gel electrophoresis
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis on 12 % acrylamide slab gels was performed as described (29) .
RESULTS
Isolation and sequencing of the hgprt from T.brucei
Preliminary attempts to isolate the hgprt from T. brucei, as well as from other parasites of the Trypanosomatidae family, by cross hybridization under low stringency conditions to either the mouse (23), 5. mansoni (24), or P. fakiparum (25) hgprt cDNAs were unsuccessful. Consequently, the PCR was exploited to amplify fragments of the T. brucei hpgrt from genomic DNA using primers to conserved amino acid sequences among other eukaryotic HGPRT proteins (22) (23) (24) (25) . A 174 bp fragment that encoded a fragment of the T. brucei hgprt was amplified and used as a probe for the isolation of hgprt cDNAs from a cDNA library. Nucleotide sequence analysis of the longest cDNA, a 1.4 kb fragment, confirmed that it lacked the 5' end of the protein coding segment of the T. brucei hgprt. Therefore, the 1.4 kb cDNA was employed in turn to isolate the hgprt from a genomic library. A 4.2 kb SaR-Kpril fragment was subcloned into pBluescript, and the protein coding segment of hgprt was sequenced in both directions. The nucleotide and predicted amino Figure 1 ). Moreover, PCR of reverse transcribed RN A indicated that the first nucleotide of the mature hgprt transcript is located 59 nucleotides 5' to the start codon (marked by an asterisk in Figure 1 ). The predicted amino acid sequence of the T. brucei HGPRT was aligned with the primary structures of the human (22), 5. mansoni (24) , P. falciparum (25) , and Vibrio harveyi (40) counterparts (Figure 2 ). The T. brucei HGPRT is between 8 and 21 amino acids shorter than its eukaryotic equivalents but 34 amino acids longer than the prokaryotic HPRT. Examination of all the PRT sequences after alignment also disclosed a variety of amino acid deletions and insertions throughout their primary structures. When each of the PRTs was examined for amino acid identities in a pairwise fashion to the other enzymes, the T. brucei HGPRT appeared to be the most divergent and exhibited greater homology toward the V. harveyi HPRT than to the eukaryotic HGPRTs (Table I ). The degree of similarity among the eukaryotic HGPRT sequences conforms to the observed phylogenetic relationships among the organisms inferred from analysis of their rRNA sequences (41) .
Among all the aligned PRT sequences, there are few regions of extensive homology. Unsurprisingly, the stretches of amino Figure 2 . Alignment of the amino acid sequences of the T. brucei, human, S. mansoni, and P. falciparum HGPRTs and the V. harveyi HPRT. The predicted primary structure of the T. brucei HGPRT protein was aligned with those deduced from the nucleotide sequences of the human (22), 5. mansoni (24) , and P. falciparum (25) hgprt cDNAs and the V. harveyi hprt (40) according to the CLUSTAL V program, a modification of that described by Higgins and Sharp (30) . Amino acids identical among the five aligned PRT sequences are indicated by asterisks below the aligned sequences, whereas nonidentical amino acids with similarity scores > 10, as calculated by the log-odds amino acid similarity matix of Dayhoff (31) , are denoted with a dot below the amino acid sequences. Amino acid positions of the five proteins are designated numerically on the right. The amino acid sequences to which the PCR primers used in the amplification of the T. brucei hgprt fragment from genomic DNA were derived and the putative purine binding site of the PRTs (24,42) are designated. domain lies a central Arg residue and a Thr-Ala dipeptide in the P. falciparum enzyme (25) that distinguishes the malarial purine binding site from those of the human (22), S. mansoni (24) , T. brucei, and V. harveyi (40) . A conserved aromatic amino acid and an Ala-Asp are found at these positions in the other HPRTs. These striking differences may account for the unique ability of the malarial HGPRT to recognize xanthine as a substrate (44) . The other eukaryotic HGPRTs, as well as the prokaryotic HPRT, do not phosphoribosylate xanthine. A third region located proximal to the COOH termini, a stretch of amino acids for which no function has been ascribed, is also highly conserved among the aligned PRT sequences. Between residues 162 and 181 of the T. brucei HGPRT, there are 7 amino acid identities and 9 similarities within this region. Although no known function has been imputed to this region of the protein, several naturally occurring missense mutations in this regions confer HGPRTase deficiency in humans and elevate apparent K m values for both substrates dramatically (45) , indicating the importance of these sequences in catalytic competence and substrate binding. It is worth noting that the amino acid regions outside the 3 conserved areas are highly divergent among the PRT proteins with only an occasional single amino acid identical among the 5 aligned PRT sequences. Among the aligned sequences (Figure 2) , the longest stretch of amino acid identity outside the 3 conserved regions is 2 amino acids, a Ser-Tyr dipeptide corresponding to residues 83 and 84 of the T. brucei HGPRT.
Size and quantitation of T. brucei hgprt transcripts A Northern blot of total RNA isolated from trypomastigote, stumpy, and procyclic forms of IsTAR 1 T. brucei was probed with the 774 bp Ndel-Sall fragment that contains die protein coding portion of the hgprt. Two transcripts of 1.4 and 1.9 kb, each large enough to encode the entire trypanosome HGPRT, were recognized by this probe in all 3 developmental stages of the parasite (Figure 3) . The hybridization signals to both bands were equivalent in the 3 life forms, and the level of hgprt expression did not appear to be developmental^ regulated. The same two transcripts are observed in RNA from TREU667 procyclic forms (data not shown).
Southern analysis of the hgprt locus in T.brucei
As a number of genes in T. brucei are arranged in tandemly repeated arrays (44, 45) , the hgprt locus in TREU667 T. brucei was analyzed for repeated sequences by restriction enzyme analysis and Southern blotting (Figure 4) . T. brucei DNA was digested with a variety of restriction enzymes, blotted onto Nytran filters, and probed with the 774 bp Ndel-Sall fragment. Restriction enzymes Ndel, £coRI, and SacH, each of which cleaves the hgprt once, excised 3 or more fragments of dissimilar sizes that hybridized to the hgprt probe ( Figure 4) . If hgprt was organized as a tandem repeat within the T. brucei genome, this strategy would yield a prominent band of identical size in all lanes of a Southern blot in which the genomic DNA had been digested with a single cutter. Moreover, digestion of T. brucei DNA with either A val, HindUl, or Kpnl, which do not cleave within hgprt, generates two DNA fragments that hybridize to the hgprt. These data suggest that hgprt is present in at least two copies within the T. brucei genome. Although the restriction pattern depicted in Figure 4 does not rule out the possibility that the hgprt locus consists of two very different alleles, this conjecture requires restriction fragment length polymorphisms for every restriction enzyme tested.
Overexpression of hgprt in E.coli
After appropriate PCR mutagenesis, the T. brucei hgprt was ligated into the E. coli expression plasmid pBAce and transformed into S06O6 E. coli that are genetically deficient in both the HPRT and XGPRT activities. Nucleotide sequencing demonstrated that die primary structures of die recombinant and native HGPRT enzymes were identical. After inoculation into low phosphate medium, die transformed E. coli were grown for ~ 12 hr to an = 0.9 -1.2. Further growth of cells in this induction medium to stationary phase densities severely diminished hgprt expression. S06O6 E. coli transformed with the hgprt construct expressed very high levels of HGPRT activity, whereas the same cells transformed with a control pBAce plasmid lacking hgprt expressed no HGPRT activity. Proteins from the S<£606 E. coli were then fractionated by SDS polyacrylamide gel electrophoresis and stained with Coomassie Blue. As demonstrated in Figure 5 , the recombinant T. brucei HGPRT is the predominant protein in E. coli lysates transformed with the /igprf-containing plasmid and is not detected in cells transformed with the control plasmid. The recombinant HGPRT migrates slightly more slowly than that expected from its predicted M r .
Purification and substrate specificity of T. brucei HGPRT Recombinant T. brucei HGPRT protein was purified by GTPagarose affinity chromatography followed by elution with 1.0 mM PRPP (data not shown). No HGPRT activity was present either in the void volume or in washes prior to the addition of the PRPP. As demonstrated in Figure 5 , passage over the affinity column resulted in a one step purification of the protein to homogeneity. -100 mg of pure T. brucei HGPRT could be obtained by this strategy per liter of bacterial culture. The substrate specificity of the pure recombinant trypanosome HGPRT was also evaluated. Clearly, T. brucei HGPRT prefers the naturally occurring nucleobases, hypoxanthine and guanine, as substrates but is also capable of phosphoribosylating HPP. K,,, values of 2.3 ± 0.9, 4.8 ± 0.6, and 243 ± 35 jiM and k^, values of 32 ± 4.7, 53 ± 2.9, and 4.4 ± 0.6 /tmol/ min/mg protein were calculated for the recombinant enzyme by Lineweaver-Burk analysis for hypoxanthine, guanine, and HPP, respectively ( Figure 6 ). Neither xanthine nor adenine were 
DISCUSSION
A full length hgprt gene has been isolated from a genomic library of T. brucei DNA. Unlike previously isolated parasite hgprt cDNAs that were isolated by cross hybridization to the murine hgprt cDNA, the nucleotide sequence disparity of the T. brucei hgprt gene precluded its recognition by the heterologous hgprt probes. Thus, the PCR was exploited to amplify a specific hgprt fragment from T. brucei using oligonucleotide primers generated to the PRPP binding and COOH terminal sequences that are highly conserved among the mammalian (22, 23) , S. mansoni (24) , and P. falciparum (25) HGPRTs. Nucleotide sequence analysis revealed that the primary structure of the T. brucei HGPRT protein contained more amino acid identities with the V. harveyi HPRT than to its counterpart from higher eukaryotes. This homology cannot be explained by substrate specificity variations, since the prokaryotic enzyme phosphoribosylates hypoxanthine exclusively, while xanthine and guanine are recognized by a biochemically and genetically distinct protein (37, 40, 48) . The lack of homology between the T. brucei and eukaryotic HGPRTs is somewhat surprising in view of the extensive homology observed between the primary structures of the ODC (49) and IMP dehydrogenase (50) proteins from T. brucei and mouse. The T. brucei and murine ODC enzymes exhibit a 69 % amino acid identity over a core region of 376 amino acids with no gaps in the alignment, whereas the T. brucei and human IMP dehydrogenase proteins are identical in 53 % of their residues with only a few small gaps in the computed alignment. The amino acid sequence divergence among the HGPRT proteins from phylogenetically diverse organisms suggests that conservation of primary structure is not critical for enzyme function. Despite the extensive divergence of primary structures, analyses of the secondary structures of mammalian and parasite HGPRTs using the algorithm of Chou and Fasman (51), predict several common features, including a /3-a-/3 structure characteristic of a mononucleotide fold involved in PRPP binding to PRTs (24, 42 , and data not shown).
The hgprt gene is not differentially expressed in T. brucei. The lack of differential expression of HGPRT is unsurprising in view of the facts that both the procyclic and bloodstream forms of T. brucei are auxotrophic for purines (10, 13) and that hypoxanthine is a predominant environmental source of purines for the parasite (52) . Whether the two transcripts are derived from the same or different genetic loci is not known in view of the fact that these parasites appear to contain more than one hgprt copy. As Southern blot and sequence analysis of cDNA generated and amplified from the 5' portion of hgprt mRNA revealed only a single fragment, the data suggest that the hgprt transcripts are heterogeneous in their 3' termini. This conjecture is supported by the results of experiments in which PCR of reverse transcribed RNA, using a sense primer 3' to the hgprt protein coding region and oligo (dT), amplified two DNA fragments that differed in size by -500 bp.
The ability to overexpress and purify the T. brucei HGPRT in an E. coli background genetically deficient in both HPRT and XGPRT has established that the enzyme is specific for hypoxanthine and guanine and does not recognize either xanthine or adenine. The existence of separate PRTs for xanthine and adenine is supported by experimental evidence demonstrating the differential incorporation of radiolabeled purine bases into nucleotide pools in both procyclic and bloodstream forms of T. brucei species and by the fact that T. brucei lack adenine deaminase activity (10, 13) , an enzyme that is expressed to high levels in promastigotes of Leishmania (53) . Moreover, expression of the recombinant T. brucei HGPRT in the S06O6 E. coli establishes that the enzyme can recognize HPP as a substrate. The procyclic forms of T. b. brucei, T. b. gambiense, and T. b. rhodesiense can further convert HPP to aminopyrazolpyrimidine nucleotides and incorporates the triphosphate of the latter into RNA (17) . This metabolic sequence does not exist in humans or mammals, and the procyclic forms of the parasite are selectively sensitive to HPP. HPP exhibits no toxicity toward humans and is widely used as an hypouricemic agent in the treatment of hyperuricemia and gout (18) . Although, the curative effects of HPP against African trypanosomiasis in humans have not been established, the pyrazolopyrimidine exhibits demonstrable therapeutic efficacy in preliminary clinical trials against both cutaneous leishmaniasis (54) and Chagas disease (55) . Moreover, as hypoxanthine is the salvageable purine present in the highest concentrations in human blood and cerebrospinal fluid (52) , the milieus inhabited by the parasite, HGPRT is likely to provide a critical nutritional function in T. brucei. The selective toxicity of HPP toward T. brucei and the potentially central role of HGPRT in purine salvage imply that the parasite HGPRT may provide a biochemically rational target for the therapeutic manipulation of African sleeping sickness.
Although virtually all antiparasitic regimens are empirical in design, a precedent for rationally based treatments of African trypanosomiasis exists. a-Difluoromethylornithine (DFMO), an irreversible inhibitor of ODC, the rate limiting step in polyamine biosynthesis (56) , has shown considerable promise in the treatment of some forms of African trypanosomiasis (57) . The therapeutic efficacy of DFMO is based on the rapid rate of turnover of the mammalian enzyme in contrast to the T. brucei ODC (49, 58) . The instability of the mammalian ODC is conferred by a COOH terminus rich in PEST sequences, a sequence missing in the T. brucei ODC. Although, DFMO treatment does not manifest the toxic side effects of the conventional antitrypanosomal reagents and is effective after central nervous system involvement, its administration is prolonged and expensive, and the drug is not particularly effective toward T. b. rhodesiense (57) . Moreover, resistance to DFMO has been demonstrated in vitro (59, 60) . Thus, the search for newer and improved therapies for the treatment of African trypanosomiasis are imperative. The isolation of the molecular clone encoding the T. brucei HGPRT and the functional overexpression and purification of large quantities of pure recombinant HGPRT enzyme from E. coli provide an avenue for a structure-based strategy for the design and discovery of novel HGPRT substrate analogs or HGPRTase inhibitors that can serve as effective agents in the treatment of African trypanosomiasis or of any other parasitic disease.
